Chlamydia Infection Diagnostics and Therapeutics Market Report 2024

The chlamydia infection diagnostics market size has grown rapidly in recent years. It will grow from $1.12 billion in 2023 to $1.25 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The rise during the historical period can be linked to heightened awareness and education, government funding, a growing incidence of sexually transmitted infections (STIs), and improved healthcare access.

The chlamydia infection diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.94 billion in 2028 at a compound annual growth rate (CAGR) of 11.6%. The anticipated growth in the forecast period can be attributed to the increasing need for rapid testing, enhanced global agency support, government initiatives, the demand for fast and accurate testing, and a rising incidence of chlamydia infections. Key trends during this period include advancements in molecular diagnostics, the expansion of point-of-care testing (POCT), the integration of digital health technologies, an emphasis on population screening and public health efforts, as well as the emergence of new technologies and innovations.

The increasing emphasis on preventive healthcare is anticipated to drive growth in the chlamydia infection diagnostics market. Preventive healthcare focuses on averting diseases through measures such as regular check-ups, vaccinations, and lifestyle changes, rather than addressing them post-occurrence. The aim is to lower healthcare expenses, enhance quality of life, and prevent chronic conditions through early detection and proactive care. This approach is crucial for chlamydia diagnostics, as it promotes early detection, education, and routine screening, which help in curbing the spread and complications of chlamydia infections. For example, in May 2023, the National Health Service (NHS) reported that around 23.02 million diagnostic tests were performed in March 2023, an increase of 223,100 tests from March 2022. Additionally, the number of patients awaiting a critical diagnostic test rose to 16.28 million in March 2023, up by 59,400 from the previous year. Thus, the heightened focus on preventive healthcare is a key factor driving the chlamydia infection diagnostics market.

Leading companies in the chlamydia infection diagnostics market are concentrating on developing advanced products, such as molecular point-of-care testing platforms, to maintain a competitive advantage. Molecular point-of-care (POC) testing platforms are diagnostic tools that detect and analyze specific nucleic acids (DNA or RNA) of pathogens directly at the patient care site. For instance, in March 2021, Binx Health Inc., a US-based health technology firm, announced that the US Food and Drug Administration (FDA) had granted a clinical laboratory improvement amendments (CLIA) waiver for their Binx IO system. This molecular point-of-care testing platform can deliver central laboratory-quality results within approximately 30 minutes for detecting chlamydia (CT) and gonorrhea (NG). The system had already received 510(k) clearance from the FDA for testing male and female samples in moderate and high-complexity settings.

In April 2022, Chiricahua Community Health Centers Inc. (CCHCI), a US-based healthcare service provider, partnered with The Body Agency Collective (TBAC) and Visby Medical, Inc. to enhance the diagnosis and treatment of sexually transmitted infections (STIs). This collaboration will utilize a PCR diagnostic device called the Sexual Health Click Test, capable of detecting three common and treatable STIs in women, gonorrhea, chlamydia, and trichomoniasis. TBAC is a US-based foundation that offers accessible sexual and reproductive health education, products, and services for women and girls. Visby Medical, Inc. is a US-based medical technology company focused on developing innovative diagnostic solutions to improve chlamydia diagnosis and treatment.

Major companies operating in the chlamydia infection diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton, Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Cepheid, Meridian Bioscience Inc., Sekisui Diagnostics, Copan Diagnostics.

North America was the largest region in the chlamydia infection diagnostics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chlamydia infection diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the chlamydia infection diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Chlamydia infection diagnostics involve methods and procedures used to detect and confirm the presence of Chlamydia trachomatis bacteria in individuals who may have a chlamydial infection. Accurate diagnostics are essential for proper diagnosis, treatment planning, and preventing further spread.

The primary diagnostic tests for chlamydia infection include culture tests, nucleic acid amplification tests (NAAT), direct fluorescent antibody tests, serology tests, among others. A culture test is a procedure where patient samples are cultured to identify microorganisms, which aids in diagnosing infections and determining the appropriate treatment. This test is applicable to various types of chlamydial infections, including genital, rectal, and ocular chlamydia. These tests are used in hospitals, specialty clinics, and diagnostic centers, serving different users such as diagnostic and therapeutic professionals.

The chlamydia infection diagnostics market research report is one of a series of new reports that provides chlamydia infection diagnostics market statistics, including chlamydia infection diagnostics industry global market size, regional shares, competitors with a chlamydia infection diagnostics market share, detailed chlamydia infection diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia infection diagnostics industry. This chlamydia infection diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chlamydia infection diagnostics market includes revenues earned by entities by providing services such as laboratory testing services, point-of-care testing, and consultation and diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.